Neurolixis, Inc. today announced the appointment of Dr. Christopher Jankosky, MD, MPH, as its Chief Medical Officer. 
"We are thrilled to have Dr. Jankosky join our team as Chief Medical Officer," said Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis. "His deep understanding of the medical needs in the neurology area and of the drug development process will be invaluable as we continue to advance our pipeline and bring new therapies to patients."
Dr. Jankosky has spent over 20 years in senior medical and healthcare roles. As Chief Medical Officer, Dr. Jankosky will be responsible for leading the company's clinical development strategies, overseeing the design and conduct of clinical trials, and ensuring that Neurolixis remains at the forefront of innovation in the industry. He had previously been a member of the Neurolixis Scientific Advisory Board since 2021.
"I am honored to join Neurolixis and be part of such a talented and dedicated team," said Dr. Jankosky. "I am passionate about finding solutions to unmet medical needs and excited to contribute to Neurolixis' mission of improving the lives of patients through cutting-edge treatments."